Top Cited 2019 Impact Factor
The global burden of melanoma: results from the Global Burden of Disease Study 2015
C. Karimkhani, A.C. Green, T. Nijsten et al.
British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017
C.H. Smith, Z.K. Jabbar-Lopez, Z.Z. Yiu et al.
Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis
A. Egeberg, M.B. Ottosen, R. Gniadecki et al.
Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity
C.C. Zouboulis, T. Tzellos, A. Kyrgidis et al.
No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis
B.E. Strober, R.G.B. Langley, A. Menter et al.
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)
M. de Bruin-Weller, D. Thaçi, C.H. Smith et al.
Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management
D.M. Saunte, U. Mrowietz, L. Puig and C. Zachariae
The role of the skin microbiome in atopic dermatitis: a systematic review
R.D. Bjerre, J. Bandier, L. Skov et al.
Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study
H. Nakagawa, O. Nemoto, A. Igarashi and T. Nagata
Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis)
A.V. Marzano, G. Damiani, I. Ceccherini et al.